Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339479 | 0.80 | ALDH1A1 (0.65) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL299775 | 0.70 | ALDH1A1 (0.54) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL12340927 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL3394308 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL701494 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL5077071 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL7829285 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL5077077 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL5074604 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL13814464 | 0.67 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| EP-1789388-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | claimed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006026532-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | ALDH1A1 1161/4885CA1 600/4885CA2 1691/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ALDH1A1 1971/4885CA1 1599/4885CA2 3726/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | ALDH1A1 1161/4885CA1 600/4885CA2 1691/4885 |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | AMY1A, AMY2A, DNPEP | ALDH1A1 826/4885CA1 656/4885CA2 3007/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | ALDH1A1 1161/4885CA1 600/4885CA2 1691/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | ALDH1A1 1971/4885CA1 1599/4885CA2 3726/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ALDH1A1 1971/4885CA1 1599/4885CA2 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.